BRIEF published on 11/19/2024 at 22:35, 3 days 11 hours ago Abivax Launches ATM Program on Nasdaq Common Shares Biotechnology Funding Nasdaq ATM Program
PRESS RELEASE published on 11/19/2024 at 22:30, 3 days 12 hours ago Abivax Establishes an At-the-Market (ATM) Program on Nasdaq Abivax establishes an At-the-Market (ATM) Program on Nasdaq, allowing issuance and sale of ordinary shares to raise up to $150 million. Implementation involves Piper Sandler & Co. as sales agent Ordinary Shares Abivax Nasdaq ATM Program Piper Sandler
BRIEF published on 11/14/2024 at 22:06, 8 days 12 hours ago Abivax Releases Q3 2024 Financial Results Financial Results Biotechnology Abivax Ulcerative Colitis Q3 2024
PRESS RELEASE published on 11/14/2024 at 22:01, 8 days 12 hours ago Abivax presents third quarter 2024 key financial information Abivax presents key financial information for the third quarter of 2024. The company announced updates on operational goals and debt status. Details on Abivax's cash and principal debt outstanding are provided Financial Information Abivax Quarter Results Clinical-stage Biotechnology Debt Status
BRIEF published on 11/13/2024 at 22:06, 9 days 12 hours ago Abivax Appoints Mark Stenhouse as Observer and Strategic Advisor Biotechnology Abivax Obefazimod Appointment Mark Stenhouse
PRESS RELEASE published on 11/13/2024 at 22:01, 9 days 12 hours ago Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax Abivax appoints Mark Stenhouse, former Prometheus COO, as Board Observer & Advisor, bringing extensive biopharma experience to support clinical therapeutics development Abivax Mark Stenhouse Prometheus Board Observer Clinical Therapeutics
BRIEF published on 10/11/2024 at 18:05, 1 month 11 days ago ABIVAX terminates its liquidity contract Liquidity Contract Biotechnology Termination Trading Abivax
BRIEF published on 10/11/2024 at 18:05, 1 month 11 days ago ABIVAX: Number of Shares and Voting Rights as of September 30, 2024 Euronext Paris Share Capital Voting Rights AMF Abivax
PRESS RELEASE published on 10/11/2024 at 18:00, 1 month 11 days ago ABIVAX Announces Termination of Liquidity Contract and Publishes End of Contract Statement. Abivax terminates liquidity contract with TSAF SA, releasing details of assets in the account and transactions. Company focuses on developing therapies for chronic inflammatory diseases Liquidity Contract Termination Abivax Therapeutics Immune Response
BRIEF published on 10/07/2024 at 22:06, 1 month 15 days ago Abivax celebrates Nobel Prize for microRNA discovery Abivax Obefazimod Medical Research MicroRNA Nobel Prize
Published on 11/22/2024 at 23:55, 10 hours 37 minutes ago Boron One Announces Early Warrant Exercise Incentive Program
Published on 11/22/2024 at 23:30, 11 hours 2 minutes ago Electric Royalties Enters Into Definitive Agreement to Acquire 0.75% Gross Revenue Royalty on Producing Punitaqui Copper Mine in Chile
Published on 11/22/2024 at 23:05, 11 hours 27 minutes ago Nexa Resources Announces Closing Transaction of Pukaqaqa Project Sale to Olympic
Published on 11/22/2024 at 22:30, 12 hours 2 minutes ago Delaforce Energy Corp. Announces Acquisition of Bouchard Well Service Ltd.
Published on 11/22/2024 at 18:14, 16 hours 17 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 11/22/2024 at 17:53, 16 hours 38 minutes ago Funding Circle Plc: POS-Transaction in Own Shares
Published on 11/22/2024 at 16:55, 17 hours 36 minutes ago EQS-Adhoc: Comment on withdrawn non-binding offer
Published on 11/22/2024 at 16:00, 18 hours 32 minutes ago Proposed cancellation of admission to trading
Published on 11/21/2024 at 06:58, 2 days 3 hours ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 2 days 15 hours ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 2 days 16 hours ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 2 days 16 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
